News

Video

Preparing Health Systems for Looming DSCSA Enforcement

Rob DeWig, VP of Healthcare Sales at Inmar, touches on looming DSCSA enforcement and the impact of Inmar's reconciliation tools.

Pharmaceutical Executive: With DSCSA enforcement looming in November 2025 how prepared are most health systems today?
Rob DeWig: I would say, you know, with a couple of extensions that have been in place around enforcement, I think we're in a lot better shape than we were originally two years ago, where there was just panic all around so I would say they're pretty the ready. The thing they're working towards now is how it'll making sure it doesn't affect their workflow. Because, you know, there's so many different things that a hospital pharmacy needs to do, just in general, and now, with adding another complexity to it to ensure that the workflow is seamless. And so that's one of the advantages of our platform, is that it doesn't take away from any workflow. It actually just makes it really seamless.

Pharmaceutical Executive: What impact does Inmar’s reconciliation tools have for a typical hospital pharmacy?

Rob DeWig: Well, I think you know what we're seeing a lot in hospital pharmacies today is the shift towards specialty because, and you know, any really ambulatory where they can bring additional revenue into a hospital. You know, it's been, long been said that, you know, inpatient pharmacy is a cost center, not true revenue generating, but it's really shifted over the last few years. And you know, with that shift into specialty, those prescriptions are very high dollar, and so it's important to recoup every dollar that you can to bring those back into your health system. And so I think without getting into actual dollars and cents there, calling out the specialty and making sure when your day sales is outstanding is decreased. I mean, two days is a big deal getting the cash flow back. And as well as a 50% reduction in write offs too, is another benefit of the program. And so you think about the increase in pricing of drugs, which has gone up every year. The complexities that we're seeing about, you know, maximum fair price being included. Now, it's just really important to have reconciliation tool that is covering all the bases to make sure you're actually getting paid for the work that you're performing.

Newsletter

Lead with insight with the Pharmaceutical Executive newsletter, featuring strategic analysis, leadership trends, and market intelligence for biopharma decision-makers.

Related Videos
Ryan Quigely
Pharmaceutical Executive
Ryan Quigely
© 2025 MJH Life Sciences

All rights reserved.